探討致癌基因KRAS在薑黃素合併FDA核准標靶用藥對人類大腸直腸癌細胞的角色

The role of KRAS gene in combination treatment of Curcumin and FDA-approved Targeted Drugs in human colorectal cancer cells

吳奇軒(Wu Chi-Shiuan)

指導教授 ： 蘇純立

國立臺灣師範大學/教育學院/人類發展與家庭學系/碩士(2016年)

https://doi.org/10.6345/NTNU202204039

摘要

['薑黃素為天然多酚類化合物，許多研究證實具有抗癌功效。大腸直腸癌在臺灣癌症死因中排名第三位，全世界約有35-45%的大腸直腸癌病患會有致癌基因KRAS突變的問題，KRAS突變也與治療產生阻抗及預後較差有關。Regorafenib為小分子多激酶抑制劑，無論病患KRAS基因狀態皆可使用，是目前治療大腸直腸癌的最後一線用藥 。本研究使用薑黃素合併Regorafenib進行實驗，使用MTT assay發現Curcumin合併Regorafenib在HCT 116（KRAS mutant）細胞的生長抑制效果顯著優於parental HT-29（KRAS wild type）細胞，以流式細胞儀分析細胞凋亡及細胞自噬結果發現HCT 116細胞的sub-G1（細胞凋亡）及AVOs（細胞自噬）的比例顯著高於parental HT-29細胞。使用HT-29 KRAS mutant inducible細胞檢測發現在HT-29 induced KRAS mutant細胞的生長抑制效果較HT-29 KRAS mutant細胞好。最後利用U0126處理HCT 116、parental HT-29細胞，發現Curcumin合併Regorafenib在KRAS mutant細胞中可能藉由標靶RAF及MEK蛋白引發合成致死作用，增加細胞死亡數量。']

關鍵字

薑黃素 ； 癌瑞格 ； 細胞自噬 ； 細胞凋亡 ； 合成致死 ； 大腸直腸癌細胞

並列摘要

['Curcumin, a polyphenol mainly from Asian foods, has been reported to exhibit anti-cancer activity. Colorectal cancer is third most common cause of cancer-related death in Taiwan. KRAS is the most frequently mutated RAS isoform, having been shown to be mutated in 35-45% of colorectal cancers (CRC) worldwide. KRAS mutation failed to targeted therapies and led to poor prognosis. Regorafenib is a FDA-approved multi-kinase inhibitor used as the last-line drug for CRC patients despite the RAS genotype. To determine whether Curcumin can enhance Regorafenib-induced cytotoxicity of CRC with KRAS mutation, CRC HCT 116 (KRAS mutant), parental HT-29 (KRAS wild-type) and KRAS mutant HT-29 (with inducible KRAS mutant gene) cells were used. MTT analysis indicated that Curcumin in the presence of Regorafenib had a higher growth inhibition on HCT 116 cells than parental HT-29 cells. Addition of Curcumin not only significantly enhanced Regorafenib-induced elevation in the percentage of cells at the sub-G1 phase (induction of apoptosis) and cells with acidic vesicular organelles (induction of autophagic flux) on HCT 116 cells, compared to that on parental HT-29 cells using flow cytometry. MTT analysis also indicated that Curcumin in the presence of Regorafenib had a higher growth inhibition on HT-29 induced KRAS mutant cells than HT-29 KRAS mutant cells. The use of MEK inhibitor U0126 increased the cytoxicity, percentage of cells at the sub-G1 phase and AVOs on HCT 116 and parental HT-29 cells.Taken together, these data suggest that Curcumin plus Regorafenib may target one more gene other than mutant KRAS and enhanced the cytotoxicity (Synthetic Lethality) on CRC, indicating a critical role of Curcumin on KRAS mutant CRC treated with Regorafenib.']

並列關鍵字

Curcumin ； Regorafenib ； Autophagy ； Apoptosis ； Synthetic lethality ； Colorectal cancer

參考文獻

Abdelsattar, Z. M., Wong, S. L., Regenbogen, S. E., Jomaa, D. M., Hardiman, K. M., & Hendren, S. (2016). Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer, 122(6), 929-934. doi:10.1002/cncr.29716

Ait Ouakrim, D., Lockett, T., Boussioutas, A., Hopper, J. L., & Jenkins, M. A. (2013). Screening participation for people at increased risk of colorectal cancer due to family history: a systematic review and meta-analysis. Fam Cancer, 12(3), 459-472. doi:10.1007/s10689-013-9658-3

Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008). Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett, 267(1), 133-164. doi:10.1016/j.canlet.2008.03.025

Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., Tabah-Fisch, I., de Gramont, A. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350(23), 2343-2351. doi:10.1056/NEJMoa032709

Aran, V., Victorino, A. P., Thuler, L. C., & Ferreira, C. G. (2016). Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. Clin Colorectal Cancer. doi:10.1016/j.clcc.2016.02.008